Venmax Drugs and Pharmaceuticals Limited (BOM:531015)
22.94
-1.06 (-4.42%)
At close: Jun 1, 2026
BOM:531015 Revenue
In the fiscal year ending March 31, 2026, Venmax Drugs and Pharmaceuticals had annual revenue of 80.25M INR with 894.04% growth. Venmax Drugs and Pharmaceuticals had revenue of 39.44M in the quarter ending March 31, 2026, with 1,084.71% growth.
Revenue
80.25M
Revenue Growth
+894.04%
P/S Ratio
3.31
Revenue / Employee
40.12M
Employees
2
Market Cap
265.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 80.25M | 72.18M | 894.04% |
| Mar 31, 2025 | 8.07M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Supha Pharmachem | 5.27B |
| Smruthi Organics | 1.02B |
| Resonance Specialties | 918.89M |
| Tyche Industries | 628.56M |
| Vasundhara Rasayans | 386.27M |
| Link Pharma Chem | 276.35M |
| Crestchem | 266.14M |
| Krebs Biochemicals & Industries | 237.32M |